H.C. Wainwright reiterated a Buy rating on Navidea, with a price target of $4.00. The company’s shares closed last Monday at $0.98. Company profile Navidea Biopharmaceuticals, Inc. engages in the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through the following segments: Diagnostics, Therapeutics, and Corporate. The company was founded in 1983 and is headquartered in Dublin, OH.